Add-on activity
This activity features patient case reviews.
Program Description
Overexpression of human epidermal growth factor 2 (HER2) occurs in up to 25% of all breast cancer cases. HER2-positive breast cancer carries higher rates of disease recurrence and mortality, and 30% of local and regional diagnoses progress to metastatic disease despite treatment. Recently, a newer designation of HER2-low breast cancer has been established, increasing the number of patients who may quality for HER2-targeted therapies. Monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates are currently standard of care for metastatic disease, but new combinations and novel therapies are under investigation. This program will inform pharmacists about the mechanism of agents used for HER2-positive metastatic breast cancer, adverse effects associated with these therapies, and guideline recommendations to individualize treatment. Several patient cases discussed by clinical experts throughout the presentation will help pharmacists understand the nuances of treating patients with metastatic HER2-positive breast cancer.
Target audience: Health-system and oncology pharmacists
Type of activity: Application
Release date: December 14, 2022
Expiration date: February 14, 2023
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the relevance of human epidermal growth factor 2 (HER2) status in the selection of an appropriate targeted therapy for breast cancer
- Differentiate systemic therapies in treating metastatic HER2-positive breast cancer by pharmacology, safety, and pearls for use in clinical practice
- Employ knowledge of updated clinical guidelines to individualize treatment strategies
- Apply management strategies to recognize and resolve treatment complications and adverse effects associated with HER2-targeted therapy
Allison R. Butts, PharmD, BCOP
Pharmacist Manager, Oncology
Breast Oncology Clinical Pharmacy Specialist
Acute Care Pharmacy Services
UK HealthCare – Markey Cancer
Director, PGY2 Oncology Residency Program
UK HealthCare
Lexington, Kentucky
Michael J. Berger, PharmD, BCOP
Specialty Practice Pharmacist
Department of Pharmacy
The James Cancer Hospital at
The Ohio State University Wexner Medical Center
Columbus, Ohio
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-484-L01-P. The activity is available for CE credit through February 14, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Allison R. Butts, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: AstraZeneca, BeyondSpring Pharmaceuticals
Michael J. Berger, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Consultant: Eli Lilly advisory board – Verzenio
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Morris, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms